玻璃化冷冻与辅助生殖技术中新鲜治疗周期的消退
本文为综述,分析玻璃化冷冻技术推动冻融胚胎移植周期数显著上升的原因及现有证据,讨论其在供卵、配子与胚胎国际运输等方面的安全性与风险获益平衡,并指出该技术有望实现本刊创始主编鲍勃·爱德华兹关于胚胎冷冻保存可解决辅助生殖技术诸多挑战的预测。
要点
- 冻融胚胎移植周期数逐年显著上升,玻璃化冷冻改变了辅助生殖技术的治疗格局。
- 玻璃化冷冻的安全性问题一直是其临床应用讨论的核心,随着证据积累,不同患者群体的风险获益平衡将更清晰。
- 部分中心使用冷冻保存供卵已超过新鲜卵母细胞,高效冷冻技术也促进了配子与胚胎的国际运输。
核心结论
- 玻璃化冷冻已改变辅助生殖技术的治疗格局,冻融胚胎移植周期数显著上升,并有望实现鲍勃·爱德华兹关于胚胎冷冻保存可解决辅助生殖技术诸多挑战的预测。
研究设计与样本
- 本文为综述,检视冻融胚胎移植周期上升趋势的原因及指向其未来地位的现有证据。
主要发现
- 每年进行的冻融胚胎移植周期数显著上升,为玻璃化冷冻带来治疗格局改变提供了明确证据。
- 部分中心使用冷冻保存供卵已超过新鲜卵母细胞。
- 高效的冷冻保存技术影响了配子与胚胎的国际运输,增加了国际可及性。
临床怎么用
- 随着证据基础增长,不同患者群体(包括供卵接受者)的风险获益平衡将变得更清晰。
局限性
- 原文未报告局限性
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
The advent of vitrification has transformed the therapeutic landscape in assisted reproductive technology. Clear evidence for this is provided by the dramatic rise in the number of frozen embryo transfer (FET) cycles being carried out annually. In this review, we examine the reasons that underlie this trend and the current evidence that points to the place FET cycles will come to inhabit in the future. Safety issues have been central to the narrative around the clinical application of vitrification and, as the evidence base grows, the risk benefit balance will become clearer for different patient groups. These will include recipients of donor eggs, as in some centres the use of cryopreserved donor eggs now exceeds that of fresh oocytes. Efficient cryopreservation techniques have also affected international transport of gametes and embryos, increasing international access. The profound changes that vitrification has created promises to fulfil a prediction made by this journal's founding Editor, Bob Edwards, that embryo and cryopreservation would solve many of the challenges presented by assisted reproductive technology.
引用
- Ahuja KK, Macklon N. Vitrification and the demise of fresh treatment cycles in ART. Reprod Biomed Online. 2020. PMID: 32536540. doi:10.1016/j.rbmo.2020.03.017
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。